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Background: Temsirolimus, a selective inhibitor of the mammalian target of rapamycin, has demonstrated clinical
benefit versus investigator’s choice (INV) of therapy in patients with relapsed/refractory mantle cell lymphoma (MCL).
Methods: This post hoc study retrospectively assigned simplified Mantle Cell Lymphoma International Prognostic
Index (MIPI) scores (ie, secondary MIPI) based on parameters at the time of randomization in patients with MCL (N
= 162) who received temsirolimus 175 mg once weekly for 3 weeks followed by once-weekly 75 mg or 25 mg or
the INV of active therapy. Outcomes were analyzed according to the low-, intermediate- or high-risk category.
Results: Patient distribution by MIPI risk category was 31%, 39%, and 30% in the low-, intermediate-, and high-risk
groups, respectively. Among patients in all categories, objective response rate (complete response + partial
response) was higher in patients in the temsirolimus 175/75-mg group versus the INV group, respectively: 42%
versus 0% (low-risk); 33% versus 5% (intermediate-risk); 10% versus 0% (high-risk). Median progression-free survival
was significantly longer with temsirolimus 175/75 mg versus INV, respectively, in patients with intermediate (4.3 vs
1.9 months; P = 0.035) or high (4.5 vs 1.6 months; P = 0.0025) risk, and a trend toward improvement was observed
in patients with low risk (5.3 vs 2.6 months; P = 0.091). Improvement in median overall survival was observed with
temsirolimus 175/75 mg versus INV in low-risk patients (18.0 vs 10.5 months, respectively; P = 0.069).
Conclusions: This analysis suggests that, compared with INV, temsirolimus demonstrated benefit in all MIPI risk
categories in patients with MCL. In all treatment groups, patients with high secondary MIPI scores at baseline faced
a dismal prognosis.
Trial registration: ClinicalTrials.gov NCT00117598.
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The introduction of new therapeutic strategies has led to
improvements in response rates and/or longer progression-
free survival (PFS) in individuals who are newly diagnosed
with mantle cell lymphoma (MCL) [1-4]. However,
outcomes remain poor (median survival, <2 years) in* Correspondence: georg.hess@unimedizin-mainz.de
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first-line regimens.
Temsirolimus is a selective inhibitor of the mammalian
target of rapamycin (mTOR) signaling protein, which can
be aberrantly activated in MCL [5-7]. Several clinical
studies, including one randomized controlled trial, have
demonstrated that temsirolimus has single-agent activity
in patients with relapsed or refractory MCL [8-10]. In
Europe, temsirolimus is registered for treatment of adults
with relapsed or refractory MCL [11]. Consensus guide-
lines from the European Society for Molecular Oncologyis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Distribution of patients within each treatment
arm by simplified MIPI risk category [13,14]
Patients Low risk Intermediate risk High risk
n (%) n (%) n (%)
All patients (N = 162) 51 (31) 63 (39) 48 (30)
Temsirolimus 175/75 mg
(n = 54)
14 (26) 24 (44) 16 (30)
Temsirolimus 175/25 mg
(n = 54)
15 (28) 18 (33) 21 (39)
INV therapy (n = 54) 22 (41) 21 (39) 11 (20)
MIPI = Mantle Cell Lymphoma International Prognostic Index;
INV = Investigator’s choice.
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(greater than second line) and especially in relapsed nonfit
patients [12].
In the pivotal multicenter, randomized phase III trial
[9], 162 patients with relapsed or refractory MCL were
randomized to receive temsirolimus 175 mg once weekly
for 3 weeks followed by once-weekly doses of either
75 mg (175/75-mg regimen) or 25 mg (175/25-mg regi-
men), or the investigator’s choice (INV) of active therapy.
Treatment in the INV arm consisted primarily of single-
agent gemcitabine (42%) or fludarabine (27%), along with
a number other single agents. Temsirolimus 175/75 mg
significantly prolonged median PFS compared with INV
(4.8 vs 1.9 months; hazard ratio [HR] = 0.44; P = 0.0009)
[9]. The lower dose of temsirolimus (175/25 mg) also
showed longer median PFS (3.4 months) versus INV,
but this difference was not significant. Exploratory sub-
group analyses revealed no significant differences in PFS
benefit based on sex, Karnofsky performance score (KPS)
at baseline, stage of disease at diagnosis, bone marrow in-
volvement, number of extranodal sites or number of prior
anticancer regimens [9]. Overall survival was longer
with temsirolimus 175/75 mg than with INV, but this
difference was not significant (12.8 vs 9.7 months; P =
0.3519) [9].
Patients in the phase III trial were not assigned a risk
category at baseline, owing to the absence of a robust,
validated prognostic scoring system for MCL. Since then,
the simplified Mantle Cell Lymphoma International Prog-
nostic Index (MIPI) was validated and was shown to have
high prognostic significance for newly diagnosed patients,
but it is not formally used for patients with relapsed or
refractory disease [13-16]. The objectives of the present
study were to understand whether certain MIPI risk
groups benefit more from treatment with temsirolimus, or
if there are patients unlikely to respond to treatment, and
to evaluate the potential utility of MIPI in the context of
relapsed/refractory MCL. In this study, simplified MIPI
criteria were used to retrospectively assign prognostic
scores to patients with relapsed/refractory MCL (ie, sec-
ondary MIPI) at the time of their trial enrollment, and
outcomes were analyzed according to risk category.
Results and discussion
Patients
Baseline characteristics for the patients in the random-
ized phase III trial are provided in a prior publication
[9]. In brief, median age was 67 years (range 39–88),
81% of patients were male, 85% had KPS ≥80, and 46%
had bone marrow involvement. The three treatment
groups were generally well balanced with respect to base-
line characteristics. An exception was that blastoid hist-
ology was noted for zero, nine, and four patients in the
temsirolimus 175/75-mg, 175/25-mg, and INV groups,respectively. The median number of prior regimens was
three in both temsirolimus groups and four in the INV
group. Approximately one third of the patients had under-
gone autologous hematopoietic stem-cell transplantation
following high-dose therapy.
All 162 patients were assigned simplified MIPI scores
based on baseline characteristics at their time of enroll-
ment. Of the 162 patients, 14 were missing one MIPI value,
one patient was missing two MIPI values, and two patients
were missing three MIPI values. Patient distribution was
relatively even across the low (n = 51), intermediate (n =
63), and high (n = 48) MIPI risk categories (Table 1).
MIPI distributions were comparable, with the excep-
tion of a greater proportion of intermediate-risk patients
in the temsirolimus 175/75-mg arm than in the temsiroli-
mus 175/25-mg arm (44% and 33%, respectively; Table 1).
The INV arm had a greater proportion of low-risk patients
and a lower proportion of high-risk patients relative to
both of temsirolimus treatment arms (Table 1). Of the
13 patients with blastoid variant, nine were classified as
high risk (175/25 mg [n = 7] and INV [n = 2]) and four
were classified as intermediate risk (175/25 mg [n = 2]
and INV [n = 2]).
Treatment response
Assessment of best response was available for 123 (76%)
patients. Because the distribution of the 39 patients who
did not have tumor assessments available was imbalanced
across these small subsets, tumor responses are reported
for the evaluable population. Among patients in all MIPI
categories, objective response rate (complete response
[CR] + partial response [PR]) was higher in the temsiro-
limus 175/75-mg group compared with the INV arm,
respectively: 42% versus 0% (low risk), 33% versus 5%
(intermediate risk), and 10% versus 0% (high risk).
Complete response was achieved in one patient in each
of the two treatment groups; both were classified as
intermediate MIPI. In the temsirolimus 175/25-mg group,
no CR was observed and the objective response rate by
MIPI category was 15% (low risk), 7% (intermediate risk),
and 0% (high risk).
Table 3 Treatment duration in each treatment arm by
simplified MIPI risk category [13,14]
Treatment Low risk Intermediate risk High risk
Temsirolimus 175/75 mg
n 14 24 16
Mean (std dev), weeks 32.4 (22.0) 21.1 (24.8) 10.5 (8.8)
Temsirolimus 175/25 mg
n 15 18 21
Mean (std dev), weeks 39.0 (42.3) 17.6 (11.4) 11.7 (12.4)
INV therapy
n 21 21 11
Mean (std dev), weeks 8.1 (7.8) 9.8 (10.3) 3.3 (2.4)
MIPI =Mantle Cell Lymphoma International Prognostic Index; std dev = standard
deviation; INV = Investigator’s choice.
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studies; however, patients can be asymptomatic for long
periods. Furthermore, because commonly used regimens
administered in the INV group achieved almost no object-
ive responses (one CR, no PR) in these heavily pretreated
patients, disease stabilization may be even more relevant
in this setting. When analyzed by MIPI categories, higher
clinical benefit rates (CBRs), calculated here as CR + PR +
SD ≥8 weeks, were observed in the temsirolimus 175/75-
mg arm versus the INV arm for patients in all risk groups
(Table 2). Among low-risk patients, CBR was 75%, 77%,
and 36% with temsirolimus 175/75 mg, temsirolimus 175/
25 mg, and INV, respectively. Intermediate-risk patients
had CBRs of 61%, 33%, and 40% in the respective treat-
ment groups. For high-risk patients, CBRs were 80% and
33% in the temsirolimus 175/75 and 175/25 arms, respect-
ively, whereas no patient achieved clinical benefit in the
INV arm. These results suggest that patients in all second-
ary MIPI groups may derive some clinical benefit from
temsirolimus. In addition, treatment duration was more
sustained in patients administered temsirolimus 175/
75 mg or 175/25 mg compared with INV-treated patients
in all MIPI risk categories (Table 3). Although there could
be different reasons why, in patients with SD, the doctor
and/or patient decide to continue temsirolimus therapy,
the longer treatment duration observed with temsirolimus
may provide an indirect sign of clinical benefit.
Progression-free survival and overall survival
Temsirolimus 175/75 mg significantly improved PFS ver-
sus INV in intermediate-risk (P = 0.035) and high-risk
(P = 0.0025) patients, and a trend toward improvement
was observed in low-risk patients (Figure 1; Table 4). In
general, median PFS was longer in patients of all risk
groups in the temsirolimus 175/75-mg group than for
those in the INV group (Table 4). Among low-risk pa-
tients in the temsirolimus 175/25-mg group, medianTable 2 Number of evaluable patients (%) with stable
disease or better response* by MIPI risk category [13,14]
n/N (%) [n]
Treatment Low risk Intermediate risk High risk
Temsirolimus 175/75 mg 9/12 (75) 11/18 (61) 8/10 (80)
[5 PR, 4 SD] [1 CR, 5 PR, 5 SD] [1 PR, 7 SD]
Temsirolimus 175/25 mg 10/13 (77) 5/15 (33) 5/15 (33)
[2 PR, 8 SD] [1 PR, 4 SD] [5 SD]
INV therapy 4/11 (36) 8/20 (40) 0/9 (0)
[4 SD] [1 CR, 7 SD]
*Disease assessment was based on radiographic review by independent
radiologists and review of clinical data by independent oncologists; evaluable
patients were those with tumor assessment available.
MIPI = Mantle Cell Lymphoma International Prognostic Index; PR = partial
response; SD = stable disease ≥8 weeks; CR = complete response;
INV = Investigator’s choice.PFS was 3.6 months longer than in the INV group, but
this difference was not statistically significant. Similar
median PFS were observed for the different patient co-
horts (exclusion of patients with blastoid variant, exclu-
sion of patients with missing MIPI values, and exclusion
of patients with both blastoid variant and/or at least one
missing MIPI value) compared with the analysis of all
patients, except for the longer PFS observed in low-risk
patients after patients with missing MIPI values were ex-
cluded (Table 4). A possible explanation for the longer
PFS found after patients with missing MIPI values were
excluded from the low-risk group is that this low-risk
group might include patients that should have probably
been assigned a higher risk level if all MIPI values were
recorded for them. By excluding patients with missing
MIPI values from this low-risk group, the true value of
temsirolimus 175/75 mg becomes more evident.
Mean overall survival (OS) in patients treated with
temsirolimus 175/75 mg was 18.0 months in low-risk,
12.8 months in intermediate-risk, and 5.3 months in high-
risk groups (Table 4). Though not statistically significant, a
7.5 month improvement in median OS was observed in
low-risk patients with temsirolimus 175/75 mg compared
with INV (18.0 vs 10.5 months; P = 0.069). Similar OS re-
sults observed for the different patient cohorts with ex-
cluded patients (Table 4).
Safety
For all treatment groups, low-risk patients had longer du-
rations of exposure than did high-risk patients (Table 3). In
both temsirolimus arms, the mean duration of treatment
by MIPI risk category was: Low > Intermediate >High. For
the INV arm, mean treatment durations were Low ≈ Inter-
mediate >High (Table 3).
Among patients treated with temsirolimus 175/75 mg,
grade 3 or 4 thrombocytopenia or infection appeared to
occur less frequently in low-risk patients than in high-
risk patients; no incidence pattern was noted for grade 3
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Figure 1 Kaplan-Meier plots of progression-free survival by MIPI risk group. (A) Low-risk group, (B) intermediate-risk group, and (C) high-risk
group. Log-rank P values given for temsirolimus versus investigator’s choice of therapy. Statistical analyses shown are for illustrative purposes; the
phase III trial was not powered to detect differences in progression-free survival for subsets by MIPI risk categories. MIPI = Mantle Cell Lymphoma
International Prognostic Index; TEMSR 25 mg= temsirolimus 25 mg administered once weekly after three weekly doses of 175 mg; TEMSR 75 mg=
temsirolimus 75 mg administered once weekly after three weekly doses of 175 mg.
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at least one dose delay by simplified MIPI risk category
are provided online in Additional file 1: Table S1.
Prognostic factors in relapsed/refractory MCL
For newly diagnosed patients, MIPI classification is in-
creasingly incorporated in clinical trial designs for stratifi-
cation, as well as in clinical practice to inform treatmentdecisions [16]. Although not formally established, second-
ary MIPI in relapse is now frequently used in trials of re-
lapsed/refractory MCL [13,14,17].
In our analysis, secondary MIPI classification, which was
calculated for patients with relapsed/refractory MCL, re-
vealed the potential for robust prognostic separation within
our randomized phase III trial, although data were not
available for all patients [9]. MIPI scores were observed to
Table 4 Progression-free survival by MIPI risk category and by analyzed cohort











All n = 14 n = 15 n = 22 n = 14 n = 15 n = 22
5.3 (4.2, 10.9) 6.2 (3.5, 10.9) 2.6 (2.1, 5.4) 18.0 (11.1, 22.3) 14.5 (11.0, NA) 10.5 (6.7, 16.6)
Blastoid excluded n = 14 n = 15 n = 22 n = 14 n = 15 n = 22
5.3 (4.2, 10.9) 6.2 (3.5, 10.9) 2.6 (2.1, 5.4) 18.0 (11.1, 22.3) 14.5 (11.0, NA) 10.5 (6.7, 16.6)
Missing values for MIPI excluded n = 12 n = 13 n = 16 n = 12 n = 13 n = 16
10.9 (4.2, 10.9) 6.2 (1.9, 10.9) 2.9 (2.4, 9.7) 18.0* (14.1, 22.3) 14.5 (11.0, NA) 9.5 (5.3, 16.6)
Blastoid and missing values excluded n = 12 n = 13 n = 16 n = 12 n = 13 n = 16
10.9 (4.2, 10.9) 6.2 (1.9, 10.9) 2.9 (2.4, 9.7) 18.0* (14.1, 22.3) 14.5 (11.0, NA) 9.5 (5.3, 16.6)
Intermediate risk
All n = 24 n = 18 n = 21 n = 24 n = 18 n = 21
4.3* (2.9, 9.1) 3.4 (2.6, 3.7) 1.9 (1.6, 4.0) 12.8 (8.1, NE) 8.8 (8.1, 20.6) 12.4 (5.7, 15.1)
Blastoid excluded n = 24 n = 16 n = 19 n = 24 n = 16 n = 19
4.3 (2.9, 9.1) 3.4 (1.8, 7.0) 1.9 (1.6, 4.0) 12.8 (8.1, NA) 8.8 (8.1, 20.6) 13.6 (5.7, NA)
Missing values for MIPI excluded n = 22 n = 18 n = 19 n = 22 n = 18 n = 19
4.8* (3.1, 9.1) 3.4 (2.6, 3.7) 1.9 (1.3, 4.0) 14.3 (10.0, NA) 8.8 (8.1, 20.6) 12.4 (5.7, 15.1)
Blastoid and missing values excluded n = 22 n = 16 n = 17 n = 22 n = 16 n = 17
4.8* (3.1, 9.1) 3.4 (1.8, 7.0) 1.9 (1.3, 4.6) 14.3 (10.0, NA) 8.8 (8.1, 20.6) 12.4 (5.7, NA)
High risk
All n = 16 n = 21 n = 11 n = 16 n = 21 n = 11
4.5† (1.7, 7.4) 1.9 (1.5, 3.3) 1.6 (0.7, 1.7) 5.3 (2.0, 9.9) 4.1 (2.0, 7.2) 3.5 (2.0, 4.8)
Blastoid excluded n = 16 n = 14 n = 9 n = 16 n = 14 n = 9
4.5‡ (1.7, 7.4) 1.9* (1.7, 5.6) 1.6 (0.9, 1.7) 5.3 (2.0, 9.9) 5.1 (3.3, 14.6) 3.7 (3.2, 20.4)
Missing values for MIPI excluded n = 16 n = 18 n = 11 n = 16 n = 18 n = 11
4.5† (1.7, 7.4) 1.9* (1.5, 3.3) 1.6 (0.7, 1.7) 5.3 (2.0, 9.9) 4.5 (3.3, 7.2) 3.5 (2.0, 4.8)
Blastoid and missing values excluded n = 16 n = 12 n = 9 n = 16 n = 12 n = 9
4.5‡ (1.7, 7.4) 1.9* (1.7, 5.6) 1.6 (0.9, 1.7) 5.3 (2.0, 9.9) 5.1 (3.3, 14.6) 3.7 (3.2, 20.4)
*P < 0.05 versus INV.
†P < 0.005 versus INV.
‡P < 0.01 versus INV.
MIPI = Mantle Cell Lymphoma International Prognostic Index; PFS = progression-free survival; CI = confidence interval; OS = overall survival; INV = Investigator’s
choice of therapy.
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the current study. There was a clear superiority of treat-
ment efficacy in patients with low- and intermediate-risk
MIPI categories, whereas patients in the high-risk category
did not show improved OS with any of the treatments.
Thus, MIPI scores may be applicable for prognostic evalu-
ation and risk-adapted therapeutic strategies in these hard-
to-treat patients. Furthermore, including secondary MIPI
classification in future trials may make the results from
these trials more comparable.
The results of this study should be viewed against its
limitations. First, this study was not designed to collect
MIPI parameters, which resulted in missing MIPI values
for some patients. Second, using the simplified MIPIclassification to divide patients into the different risk cat-
egories resulted in a lower number of patients available
for efficacy evaluation in each arm, thus limiting the
statistical power of many of these comparisons.
Conclusions
In conclusion, temsirolimus induced responses in all risk
groups of patients with relapsed/refractory MCL who
were retrospectively assigned MIPI scores. In all MIPI
risk groups, objective response rates and CBRs were
higher in patients treated with temsirolimus 175/75 mg
compared with INV. Trends toward improvements in
PFS and OS were also observed in all risk groups of pa-
tients treated with temsirolimus 175/75 mg versus INV.
Hess et al. Experimental Hematology & Oncology  (2015) 4:11 Page 6 of 7In all three treatment groups, patients with high risk
had dismal outcomes, suggesting that MIPI classifica-
tion may have value as a stratification factor for future
clinical trials in relapsed and/or refractory, as well as
newly diagnosed, MCL populations. Overall, this ana-
lysis indicates that earlier use of temsirolimus, when pa-
tients have favorable (low) secondary MIPI, may help to
optimize its benefit.
Design and methods
Patients and study design
This post hoc, retrospective subset analysis utilized data
from a global phase III clinical trial (ClinicalTrials.gov,
NCT00117598) in which patients with relapsed or refrac-
tory MCL were randomized to receive temsirolimus 175/
75 mg, temsirolimus 175/25 mg or INV. Patient recruit-
ment and trial design were previously described [9]. This
trial enrolled patients from June 2005 through July 2007.
Local institutional review boards at all participating cen-
ters approved the study protocol. Participating patients
provided written informed consent at the time of enroll-
ment to permit various data analyses, including explora-
tory subset analyses.
Prognostic classification
Simplified MIPI is based on four independent prognostic
factors: age, Eastern Cooperative Oncology Group (ECOG)
performance status, lactate dehydrogenase level and white
blood cell count [13,14,17]. Performance status was col-
lected in the database as KPS; for MIPI scoring, KPS was
converted to ECOG performance status as: KPS ≥80 =
ECOG 1 (0 MIPI points); KPS <80 = ECOG 2 (2 MIPI
points). Characteristics of patients recorded at the time of
enrollment were used to generate simplified MIPI scores
and to classify patients as low, intermediate or high risk at
baseline. Data were missing in some cases, resulting in a
lower number of patients available for comparison. In an
extensive analysis, we either excluded patients with blas-
toid variant, patients with missing MIPI values or patients
with both blastoid variant and/or at least one missing MIPI
value, or included all patients. When all patients were in-
cluded, the MIPI point value for a particular missing par-
ameter was handled as a zero. Due to the retrospective
nature of this analysis, we limited the analysis to the inde-
pendent assessment.
Statistical methods
Median PFS and OS were calculated using Kaplan-Meier
estimates. Significance of the treatment effect between two
treatment groups is indicated by log-rank P values ≤0.05.
The HR was calculated using a Cox proportional hazards
model. Statistical analyses shown are for explanatory pur-
poses, as the phase III trial was not powered to detect dif-
ferences in outcomes by MIPI.Additional file
Additional file 1: Table S1. Number of patients with at least one dose
delay, by simplified MIPI risk category. Number and percent of patients
who had at least one dose delay by simplified MIPI risk category and by
treatment arm.
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